TG Therapeutics announces publication of data from studies on Briumvi

TG Therapeutics (TGTX) announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating Briumvi in people with highly active relapsing forms of multiple sclerosis. The article, authored by Hans-Peter Hartung, MD, of Heinrich Heine University Dusseldorf and colleagues, was published in Neurology and Therapy. The analysis evaluated efficacy outcomes in participants with highly active disease at baseline, defined as greater than or equal to 2 relapses in the year prior and greater than or equal to 1 gadolinium-enhancing T1 lesion at baseline. Results demonstrated statistically significant reductions in relapse rates and MRI activity, as well as significantly higher rates of no evidence of disease activity, with Briumvi compared to teriflunomide.